#CreativeDisruption: Future of NexGen Therapies, Clinical Trials & Funding
Overview
Thought-provoking discussions with leaders on Next-Gen Therapies, how to prepare to get funding and how AI is changing clinical trials.
- Do you want to hear and discuss what sector’s most influential thinkers say about next-gen therapies are heading in 2026?
- Do you want to hear and discuss how AI is changing clinical trial design ?
- Do you want to hear and discuss how to best prepare yourself for your next funding round?
- Do you want to hear from biotech leaders about their challenges and experiences, and share yours?
Yes!? Then this is the event for you!
We have various big picture and analytical business leaders to lead the discussions in Next Gen Therapies, Drug Drug Discovery & Development, How Clinical Trail Design is being changed by AI, how to best prepare your company for the next funding round, and so much more. The full speaker line-up to be announced on the 3 March, you really won’t be disappointed!!
The speakers confirmed include:
Sir Tony Kouzarides, PhD, FRS, FMedSci – Director & co-founder, Milner Therapeutics Institute, Professor of Cancer Biology, University of Cambridge, CEO & co-founder, Vellos and Venture Partner, Fifty Years.
Paul Matthews, Institute Director, Rosalind Franklin Institue
Paolo Sicilano and Erik Nordkamp, PA Consulting
Olga Kubassova, President, Image Analysis Group
Peter MacLennan, CEO, TCR Solutions
James Campbell, Commercial Director, Walmer Group
Agata Nyga, CEO, Mechanome Bio
Christopher Peters, Imperial, Biomarker Lead for NIHR
Tom Mander, CEO, Pharmagene
Fin Williams, CEO, Rumii
Anthony Tennyson, CEO, Solvonis
Neil Stevens, MD, Predictive Health Intelligence and Sirius Partners
, CBO,
https://www.eventbrite.com/e/1981197316506?aff=oddtdtcreatorSrotas Health
